Prescient Therapeutics eyes ‘inflection point’, US$1.8 billion market with cancer drug PTX-100
In a sector where the right drug emerging at the right time can yield billions, Prescient...
In a sector where the right drug emerging at the right time can yield billions, Prescient...
Prescient Therapeutics (ASX: PTX) is fast emerging as the newest developer of an advanced cancer drug...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
While part of the story is an increased ability to diagnose cancers early, thanks to...
Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the company’s latest milestone —...
Prescient Therapeutics has reached a key milestone in its clinical development program, initiating its first...
The first United States clinical trial site for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF)’s Phase 2a study...
Prescient Therapeutics has crossed a major milestone in its international expansion, with the first US...
Stockhead’s Tylah Tully catches up with Prescient Therapeutics (ASX:PTX) CEO James McDonnell after the company hit a...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.